Key points are not available for this paper at this time.
A new substrate-based fragment approach for the identification of novel PTP inhibitors is presented. This method was applied to Mycobacterium tuberculosis PtpB, a promising new target for the treatment of tuberculosis. This resulted in the development of the most potent PtpB inhibitor reported to date (0.22 μM) with low molecular weight and good selectivity against a panel of other protein tyrosine phosphatases.
Soellner et al. (Wed,) studied this question.